Coblopasvir

• UNSPSC Description:

  Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection[1].

• Target Antigen:

  HCV; HCV Protease

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/coblopasvir.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@H](C(N1[C@@H](CCC1)C2=NC(C3=CC=C(C=C3)C4=C5OCOC5=C(C=C4)C6=CNC([C@H]7N(CCC7)C([C@H](C(C)C)NC(OC)=O)=O)=N6)=CN2)=O)C(C)C)OC

• Molecular Weight:

  782.88

• References & Citations:

  [1]Gao Y, et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial. Liver Int. 2020;40(11):2685-2693.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3

• CAS Number:

  1312608-46-0